Recent Advances in Small Molecule Inhibitors for the Treatment of Osteoarthritis

Author:

Lin Jianjing1ORCID,Jia Shicheng12,Zhang Weifei34,Nian Mengyuan5,Liu Peng34ORCID,Yang Li1,Zuo Jianwei1,Li Wei1,Zeng Hui34,Zhang Xintao1

Affiliation:

1. Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518036, China

2. Shantou University Medical College, Shantou 515041, China

3. Department of Bone and Joint, Peking University Shenzhen Hospital, Shenzhen 518036, China

4. National & Local Joint Engineering Research Center of Orthopedic Biomaterials, Peking University Shenzhen Hospital, Shenzhen 518036, China

5. Peking University Shenzhen Hospital, Shenzhen 518036, China

Abstract

Osteoarthritis refers to a degenerative disease with joint pain as the main symptom, and it is caused by various factors, including fibrosis, chapping, ulcers, and loss of articular cartilage. Traditional treatments can only delay the progression of osteoarthritis, and patients may need joint replacement eventually. As a class of organic compound molecules weighing less than 1000 daltons, small molecule inhibitors can target proteins as the main components of most drugs clinically. Small molecule inhibitors for osteoarthritis are under constant research. In this regard, by reviewing relevant manuscripts, small molecule inhibitors targeting MMPs, ADAMTS, IL-1, TNF, WNT, NF-κB, and other proteins were reviewed. We summarized these small molecule inhibitors with different targets and discussed disease-modifying osteoarthritis drugs based on them. These small molecule inhibitors have good inhibitory effects on osteoarthritis, and this review will provide a reference for the treatment of osteoarthritis.

Funder

Shenzhen Key Medical Subject

Shenzhen “San-Ming” Project of Medicine

National Natural Science Foundation of China

Guangdong Basic and Applied Basic Research Foundation

Bethune Charitable Foundation and CSPC Osteoporosis Research Foundation Project

Shenzhen Scientific Research Project of Health and Family Planning System

Publisher

MDPI AG

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3